Show simple item record

dc.contributor.authorDimou, P
dc.contributor.authorTrivedi, S
dc.contributor.authorLiousia, M
dc.contributor.authorD'Souza, RR
dc.contributor.authorKlampatsa, A
dc.coverage.spatialSwitzerland
dc.date.accessioned2022-06-24T10:42:58Z
dc.date.available2022-06-24T10:42:58Z
dc.date.issued2022-04-06
dc.identifierantib11020026
dc.identifier.citationAntibodies, 2022, 11 (2), pp. 26 -
dc.identifier.issn2073-4468
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5193
dc.identifier.eissn2073-4468
dc.identifier.eissn2073-4468
dc.identifier.doi10.3390/antib11020026
dc.description.abstractPrecision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. In this review, an outline of different human tumor models available in laboratory settings is provided, with a focus on the unique characteristics of PCTS. Standard PCTS generation and maintenance procedures are outlined, followed by an in-depth overview of PCTS utilization in preclinical research aiming to better understand the unique functional characteristics of cytotoxic T cells within human tumors. Furthermore, recent studies using PCTS as an ex vivo model for predicting patient responses to immunotherapies and other targeted therapies against solid tumors are thoroughly presented. Finally, the advantages and limitations of the PCTS models are discussed. PCTS are expected to gain momentum and be fully utilized as a significant tool towards better patient stratification and personalized medicine.
dc.formatElectronic
dc.format.extent26 -
dc.languageeng
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofAntibodies
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCAR-T cells
dc.subjectPCTS
dc.subjectcytotoxic T cells
dc.subjectex vivo models
dc.subjectimmunotherapy
dc.subjectorganotypic tumor slices
dc.subjectprecision-cut tumor slices
dc.subjectsolid tumors
dc.titlePrecision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
dc.typeJournal Article
dcterms.dateAccepted2022-04-01
dc.date.updated2022-06-24T10:42:30Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/antib11020026
rioxxterms.licenseref.startdate2022-04-06
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35466279
pubs.issue2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG)
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished online
pubs.volume11
icr.researchteamThor Onco Immuno Group
dc.contributor.icrauthorKlampatsa, Astero


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/